# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Acquisition significantly enhances the Company's pipeline by adding novel assets in acute and chronic anticoagulation setti...
Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.87) per share which missed the analyst consensus estimate ...
LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascul...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and maintains $32...